Pharmacological researchHumansCarcinomaNon-Small-Cell LungDrug ResistanceNeoplasm
Antibody-drug conjugates: A new twist to overcome EGFR-TKIs resistance in non-small cell lung cancer.
Shengqian Deng, Chengtao Sun, Dewen Liu, Yusha Zhang, Jizhou Zhang, Xiaojuan Li, Xu Jia, Guoyin Kai
Published: 202610.1016/j.phrs.2025.108066
Abstract
Non-small cell lung cancer (NSCLC) accounts for 80-90 % of all lung cancer cases and is characterized by high incidence and mortality rates. The epidermal growth factor receptor (EGFR), one of the most frequently mutated genes in NSCLC, has become a…
Preview only. Read the full abstract at the source